Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595462 · ClinicalTrials.gov registry record · NA
The Benefits of Consuming Hummus as an Afternoon Snack
A NA study of Appetitive Behavior, sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03595462: Completed NA study of Appetitive Behavior, sponsored by Purdue University.
NCT03595462 is a NA study of Appetitive Behavior that has completed, run by Purdue University. The registered enrollment target is 33 participants, below the 54-participant average among 11 other Appetitive Behavior trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03595462, a NA study of Appetitive Behavior, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a randomized snack study in normal to overweight adults that will test whether the consumption of different afternoon snacks will have different effects on appetite, mood, blood sugar control, and food intake. Aim 1: To examine whether the addition of hummus as part of an afternoon snack will improve diet quality, particularly through assessments of daily: * Vegetable consumption * Snacking behavior * Energy intake * Food choices Aim 2: To examine whether the addition of hummus as part of an afternoon snack will improve appetite control and satiety including assessments of: * Appetite Control (hunger, desire to eat, prospective food consumption) * Cravings (sweet, salty, savory) * Satiety (fullness) * Eating initiation Aim 3: To examine whether the addition of hummus as part of an afternoon snack will improve free-living glycemic control. Aim 4: To explore whether the addition of hummus as part of an afternoon snack will improve mood/energy states
Primary Outcome
A questionnaire assessing perceived hunger will be completed at specific times throughout each of the the 6-h testing days. The questionnaire contains a 100 mm VAS incorporating a horizontal line rating scale for each response. The questions are worded as "how strong is your feeling of" with anchors of "not all" to "extremely." The range is 0 mm (min) to 100 (max). A summation (area under the curve) will be calculated. Snacks were consumed at +0 min.
Conditions Studied
Interventions
- OTHER Snack
- OTHER No Snack
Study Locations (1)
Indiana
- Purdue University - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2018-12-20 |
| Phase | NA |
What the finished NCT03595462 record still lists
NCT03595462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 54-participant average among 11 other Appetitive Behavior trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Appetitive Behavior appearing as the primary indexed condition, and to 2 interventions - of which Snack is the first listed.
NCT03595462 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03595462 about?
NCT03595462 is a clinical study titled "The Benefits of Consuming Hummus as an Afternoon Snack". The investigators propose a randomized snack study in normal to overweight adults that will test whether the consumption of different afternoon snacks will have different effects on appetite, mood, blood sugar control, and food intake. Aim 1: To examine whether the addition of hummus as part of an ...
What is the current status of trial NCT03595462?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2018-06-08. Estimated completion is 2018-12-20.
What conditions does trial NCT03595462 study?
This clinical trial studies the following conditions: Appetitive Behavior.
What interventions are being tested in trial NCT03595462?
The interventions under investigation include: Snack (OTHER), No Snack (OTHER).
Who is sponsoring clinical trial NCT03595462?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03595462 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Appetitive Behavior
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03595462's enrollment target sits among peer trials
33 6th of 11 higher than 6 of 11 other Appetitive Behavior trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Appetitive Behavior trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Food for Thought: Executive Functioning Around Eating Among Children
RECRUITING · NA
-
Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans
RECRUITING · NA
-
Exercise, Brain Activity, and Weight Maintenance
RECRUITING · NA
-
SATISFY (geleSis100 Effects on AppeTIte Sensations, Feeding Behavior and Dietary energY)
COMPLETED · NA
-
Whole Grains, Gastric Emptying and Glycemic Response
COMPLETED · NA
-
Barley Beta-glucan, Glycemic Control, and Appetite
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI